Spire Wealth Management’s Evoke Pharma EVOK Stock Holding History

Spire Wealth Management’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-35	Closed	-$2K	–	2705
2022 Q1	$2K	Hold	35	–	–	﹤0.01%	2389
2021 Q4	$3K	Hold	35	–	–	﹤0.01%	2690
2021 Q3	$7K	Hold	35	–	–	﹤0.01%	2189
2021 Q2	$7K	Hold	35	–	–	﹤0.01%	2224
2021 Q1	$9K	Buy	+35	New	+$14K	﹤0.01%	2437

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Spire Wealth Management's EVOK Position: Q2 2022 in Review

Spire Wealth Management sold out of Evoke Pharma (EVOK) in Q2 2022, closing a stake of 35 shares — an estimated $2K sold.

Spire Wealth Management first reported a position in EVOK in Q1 2021 and held it in 5 quarters. The position peaked at $9K in Q1 2021. 12 funds tracked by Wall St. Rank hold EVOK as of Q2 2022.

Spire Wealth Management reported no remaining Evoke Pharma position as of Q2 2022 after selling out during the quarter.
Spire Wealth Management sold 35 Evoke Pharma shares in Q2 2022, an estimated $2K.
Spire Wealth Management first reported a position in Evoke Pharma in Q1 2021 and held it in 5 quarters.
Spire Wealth Management's Evoke Pharma position peaked at $9K in Q1 2021.
12 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2022.

Based on Spire Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.